| P2093 | author name string | Y Liu | |
| | J M Siegfried | |
| | C L Thomas | |
| | S Dacic | |
| | S A Belinsky | |
| | J H Schiller | |
| | A M Bernauer | |
| | C M Yingling | |
| | D M Klinge | |
| | M Tessema | |
| | S E Dahlberg | |
| P2860 | cites work | Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans | Q24309373 |
| | HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1. | Q24541580 |
| | Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer | Q24550887 |
| | Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma | Q24651026 |
| | Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain | Q24794765 |
| | Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 |
| | EGFR mutation and resistance of non-small-cell lung cancer to gefitinib | Q27824829 |
| | Phase II study of oral topotecan in advanced non-small cell lung cancer | Q28374804 |
| | Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer | Q28384157 |
| | Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers | Q28389551 |
| | Heparan sulphate proteoglycans fine-tune mammalian physiology | Q29619329 |
| | Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study | Q30434661 |
| | Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells | Q33282863 |
| | A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer | Q33331774 |
| | Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer | Q33371137 |
| | Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis | Q34134446 |
| | Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins | Q34377284 |
| | High-affinity binding of interferon-gamma to a basement membrane complex (matrigel). | Q35819475 |
| | Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. | Q36882732 |
| | ISG15 as a novel tumor biomarker for drug sensitivity. | Q36922901 |
| | Recent advances with topotecan in the treatment of lung cancer | Q36982314 |
| | 6-O-sulfation of heparan sulfate differentially regulates various fibroblast growth factor-dependent signalings in culture | Q38293479 |
| | The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation | Q39665301 |
| | Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis | Q39783590 |
| | A ubiquitin-proteasome pathway for the repair of topoisomerase I-DNA covalent complexes. | Q39976570 |
| | Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25. | Q40002585 |
| | Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels | Q40200929 |
| | Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. | Q40536091 |
| | Highly sensitive sequencing of the sulfated domains of heparan sulfate. | Q42814375 |
| | A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer | Q46487403 |
| | Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study. | Q51565999 |
| | Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway. | Q53350223 |
| | Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. | Q54061091 |
| | Expression analysis of genes involved in brain tumor progression driven by retroviral insertional mutagenesis in mice. | Q55471506 |
| P433 | issue | 37 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| P304 | page(s) | 4107-4116 | |
| P577 | publication date | 2011-12-12 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. | |
| P478 | volume | 31 | |